<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="letter" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">J. Cutan. Immunol. Allergy</journal-id>
<journal-title>Journal of Cutaneous Immunology and Allergy</journal-title>
<abbrev-journal-title abbrev-type="pubmed">J. Cutan. Immunol. Allergy</abbrev-journal-title>
<issn pub-type="epub">2574-4593</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">13728</article-id>
<article-id pub-id-type="doi">10.3389/jcia.2024.13728</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Science archive</subject>
<subj-group>
<subject>Letter to the Editor</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A case of sarcoidal foreign body reaction to permanent makeup: the involvement of M2 macrophages</article-title>
<alt-title alt-title-type="left-running-head">Furukawa et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/jcia.2024.13728">10.3389/jcia.2024.13728</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Furukawa</surname>
<given-names>Yuta</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2824230/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fukunaga</surname>
<given-names>Atsushi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/92329/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Munemoto</surname>
<given-names>Sawa</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Konishi</surname>
<given-names>Kenji</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moriwaki</surname>
<given-names>Shinichi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1068822/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Dermatology</institution>, <institution>Division of Medicine for Function and Morphology of Sensory Organs</institution>, <institution>Faculty of Medicine</institution>, <institution>Osaka Medical and Pharmaceutical University</institution>, <addr-line>Takatsuki</addr-line>, <addr-line>Osaka</addr-line>, <country>Japan</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Konishi-Kenji Skin Clinic</institution>, <addr-line>Takatsuki</addr-line>, <addr-line>Osaka</addr-line>, <country>Japan</country>
</aff>
<author-notes>
<corresp id="c001">&#x2a;Correspondence: Atsushi Fukunaga, <email>atsushi.fukunaga@ompu.ac.jp</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>10</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>7</volume>
<elocation-id>13728</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>09</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>09</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Furukawa, Fukunaga, Munemoto, Konishi and Moriwaki.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Furukawa, Fukunaga, Munemoto, Konishi and Moriwaki</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<kwd-group>
<kwd>CD68</kwd>
<kwd>CD163</kwd>
<kwd>M1 macrophage</kwd>
<kwd>M2 macrophage</kwd>
<kwd>permanent makeup</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Dear Editors,</p>
<p>A 50-year-old Japanese woman presented with a 3-month history of itching, pain, swelling, and raised yellowish lesions on her eyebrows. She had a history of permanent makeup (PMU) placement on her eyebrows 9&#xa0;years prior. Initial examination revealed distinct, slightly elevated yellow-brown plaques and significant hair loss in the affected area (<xref ref-type="fig" rid="F1">Figure 1A</xref>). Histological examination of a skin biopsy from the right eyebrow showed epithelioid granulomas with dark-brown pigments and lymphocytic infiltration, along with multinucleated giant cells without necrosis (<xref ref-type="fig" rid="F1">Figures 1B, C</xref>). Given the frequent use of iron oxide in PMU inks, we performed supplementary staining using Berlin blue, which was positive around the deposited material (<xref ref-type="fig" rid="F1">Figure 1D</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>
<bold>(A)</bold> The patient presented with a distinct, slightly elevated, yellow-brown plaque on her eyebrows. <bold>(B)</bold> Epithelioid granulomas in the dermis, with scattered dark-brown colorants, were observed on hematoxylin and eosin (H.E.) staining (H.E. &#xd7; 40). <bold>(C)</bold> Lymphocytic infiltration surrounding the granulomas and multinucleated giant cells without necrosis were observed (H.E. &#xd7; 200). <bold>(D)</bold> Berlin blue staining was positive around the deposited material (H.E. &#xd7; 100). <bold>(E)</bold> After four steroid injections, the raised yellow-brown lesion flattened partially, and some hair regrowth was observed. <bold>(F)</bold> After six steroid injections, the lesions flattened almost completely, and hair loss improved. <bold>(G)</bold> Immunofluorescence staining represents Iba1<sup>&#x2b;</sup> (ionized calcium-binding adapter molecule 1) (GeneTex, Cat. No. GTX100042, Opal&#x2122; 570, &#xd7; 40) cells for identification of both M1 and M2 macrophages. <bold>(H)</bold> Immunohistochemical staining represents iNOS<sup>&#x2b;</sup> (GeneTex,Cat.No.GTX15323, Brown stain, &#xd7;100) cells for identification of M1 macrophages. <bold>(I)</bold> Immunohistochemical staining represents CD163&#x2b; (Leica, 10D6 Cat. No. PA0090; Brown stain, &#xd7;100) cells for identification of M2 macrophages.</p>
</caption>
<graphic xlink:href="jcia-07-13728-g001.tif"/>
</fig>
<p>Physical examination, including a chest radiograph, and laboratory tests such as angiotensin-converting enzyme and soluble interleukin-2 receptor, revealed no abnormal findings. Based on clinical and histopathological findings, the patient was diagnosed with a sarcoidal foreign body reaction to PMU tattoo ink. Various treatments for sarcoidal foreign body reactions to PMU ink are effective, including topical, oral, and intralesional steroids, tacrolimus, minocycline, doxycycline, and methotrexate [<xref ref-type="bibr" rid="B1">1</xref>]. The patient had already been applying a topical steroid, with no obvious improvements. Therefore, we administered monthly steroid injections in the eyebrows using a solution (10&#xa0;mg/mL) comprised of triamcinolone acetonide and 1% lidocaine hydrochloride. Itching improved within 2&#xa0;weeks of the first steroid injection. After the fourth injection, the flat yellowbrown raised lesion partially flattened, and some hair regrowth was observed (<xref ref-type="fig" rid="F1">Figure 1E</xref>). After six injections, the lesions had almost completely flattened, hair loss had improved, and the patient expressed satisfaction with the aesthetic outcome (<xref ref-type="fig" rid="F1">Figure 1F</xref>). However, itching recurred after the injections were stopped. Therefore, injections were continued every 2&#x2013;3&#xa0;months to prevent relapse of itching.</p>
<p>Although several cases of granulomatous reactions due to PMU placement in the eyebrows have been reported, distinguishing between the initial manifestation of sarcoidosis and a sarcoidal foreign body reaction is difficult. Even patients who exhibit localized sarcoidal reactions, as in the present case, are thought to have a predisposition to sarcoidosis. Therefore, this patient should be closely followed for the development of sarcoidosis [<xref ref-type="bibr" rid="B2">2</xref>].</p>
<p>In the present case, the patient developed a sarcoid-like foreign body reaction 9&#xa0;years after a PMU procedure using blonde ink. While the composition of the ink is unknown, positive results on Berlin blue staining suggest that the ink contained iron oxides. The mechanism for this long latency period is thought to involve the gradual degradation of ink components. Chronic sun exposure may cause the ink components to break down slowly, generating highly reactive byproducts, which may function as new antigens, potentially triggering a granulomatous reaction. It is important to note that the eyebrow area is difficult to protect with sunscreen. In this case, the difficulty in applying sunscreen to the eyebrow area supports the hypothesis that sun exposure played a significant role in the development of the reaction [<xref ref-type="bibr" rid="B1">1</xref>].</p>
<p>Recent studies have identified the roles of M1 and M2 macrophages in inflammation promotion and tissue repair/inflammation suppression, respectively. Previous studies have associated sarcoidosis with a significant increase in M2 macrophages [<xref ref-type="bibr" rid="B3">3</xref>]. In the present case, we performed ionized calcium-binding adapter molecule 1 (Iba1) immunostaining to identify both M1 and M2 macrophages, along with immunostaining for inducible nitric oxide synthase (iNOS) and CD163 as M1 and M2 macrophage markers, respectively [<xref ref-type="bibr" rid="B4">4</xref>]. We observed a higher density of CD163-positive cells compared to iNOS-positive cells, indicating an increase in M2 macrophages (<xref ref-type="fig" rid="F1">Figures 1G&#x2013;I</xref>). It is hypothesized that in granuloma formation, an initial Type 1&#xa0;T helper immune response involving M1 macrophages occurs, with a transition from M1 to M2 macrophages [<xref ref-type="bibr" rid="B5">5</xref>]. Given the predominance of M2 macrophages in the present case, the transition to the resolution phase of inflammation might have been underway.</p>
<p>In summary, we successfully treated sarcoidal foreign body reactions due to PMU with local steroid injections. We identified the involvement of M2 macrophages in the observed reaction to PMU, and this contribution has not been previously reported. Thus, our findings provide new insights into the mechanisms underlying PMU-associated sarcoidal reactions.</p>
</body>
<back>
<sec sec-type="data-availability" id="s1">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s2">
<title>Ethics statement</title>
<p>Ethical approval was not required for the studies involving humans because this study presents a single case report. The studies were conducted in accordance with the local legislation and institutional requirements. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec id="s3">
<title>Author contributions</title>
<p>YF contributed to the presentation and writing of the manuscript. AF was responsible for patient treatment, supervised the manuscript, and is the corresponding author. SaM assisted AF in patient treatment. KK is the dermatologist at the clinic who first examined the patient. ShM performed the final review to assess the suitability of the manuscript for submission. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec sec-type="funding-information" id="s4">
<title>Funding</title>
<p>The authors declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec sec-type="COI-statement" id="s5">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kluger</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Sarcoidosis on tattoos: a review of the literature from 1939 to 2011</article-title>. <source>Sarcoidosis Vasc Diffuse Lung Dis</source> (<year>2013</year>) <volume>30</volume>:<fpage>86</fpage>&#x2013;<lpage>102</lpage>.</citation>
</ref>
<ref id="B2">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Infiltrative scar and scar sarcoidosis as a cutaneous manifestation of systemic sarcoidosis</article-title>. <source>J Dermatol</source> (<year>2022</year>) <volume>132</volume>:<fpage>1665</fpage>&#x2013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.14924/dermatol.132.1665</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shamaei</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mortaz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pourabdollah</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Garssen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tabarsi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Velayati</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Evidence for M2 macrophages in granulomas from pulmonary sarcoidosis: a new aspect of macrophage heterogeneity</article-title>. <source>Hum Immunol</source> (<year>2018</year>) <volume>79</volume>:<fpage>63</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.humimm.2017.10.009</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lisi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ciotti</surname>
<given-names>GMP</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kalinin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Curr&#xf2;</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dello</surname>
<given-names>RC</given-names>
</name>
<etal/>
</person-group> <article-title>Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in human glioblastoma and the surrounding normal parenchyma</article-title>. <source>Neurosci Lett</source> (<year>2017</year>) <volume>645</volume>:<fpage>106</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2017.02.076</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asai</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>What is new in the histogenesis of granulomatous skin diseases?</article-title> <source>J Dermatol</source> (<year>2017</year>) <volume>44</volume>:<fpage>297</fpage>&#x2013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1111/1346-8138.13662</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>